Volume 13, Issue 3 pp. 458-462
ORIGINAL ARTICLE

Optimus covered stent: Advanced covered stent technology for complex congenital heart disease

Gareth J. Morgan MB BaO BCh MPhil MRCPCH FSCAI

Corresponding Author

Gareth J. Morgan MB BaO BCh MPhil MRCPCH FSCAI

The Heart Institute, Children's Hospital of Colorado and University Hospital Colorado, Aurora, Colorado, USA

Correspondence Gareth J. Morgan, The Heart Institute, Children's Hospital of Colorado, Anshutz Medical Campus, Denver, CO 80045. Email: [email protected]Search for more papers by this author
Matteo Ciuffreda MD

Matteo Ciuffreda MD

Cardiovascular Department, “Papa Giovanni XXIII” Hospital, Bergamo, Italy

Search for more papers by this author
Isabella Spadoni MD

Isabella Spadoni MD

Fondazione Regione Toscana G. Monasterio, Massa, Pisa, Italy

Search for more papers by this author
Joseph DeGiovanni MD FRCP FDCPCH

Joseph DeGiovanni MD FRCP FDCPCH

Department of Pediatric Cardiology, Birmingham Children's Hospital, Birmingham, United Kingdom

Search for more papers by this author
First published: 21 February 2018
Citations: 13

Abstract

Aim

To assess the acute results of the first human use of the Optimus covered stent in complex coarctation of the aorta.

Methods and Results

We successfully implanted the Optimus covered stent in eight cases in patients whose preprocedural anatomy looked challenging for currently available covered stents. Six of the patients had native coarctation with one recoarctation following surgical repair. There were no significant complications with reduction in the mean invasive gradient from 22 to 1 mm Hg. The length of stents used ranged from 33 to 57 mm with a median shortening after expansion of 13%. Postprocedural follow-up with magnetic resonance imaging or computed tomography has not shown evidence of fracture or migration or renarrowing. The median duration of follow-up is 10 months.

Conclusions

Preliminary results show that the Optimus covered stent is safe and efficacious for use in patients with coarctation of challenging morphology. A systemic trial will be required to evaluate this stent for more widespread practice.

CONFLICT OF INTEREST

None.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.